Publications by authors named "Timothy A Brighton"

Claim this Profile
S
Serotonin Release Assay: Functional Assay for Heparin- and Vaccine-Induced (Immune) Thrombotic Thrombocytopenia.
Mayuko Kondo, Dea Donikian, Timothy A Brighton

Methods Mol Biol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Platelet-activating functional assay resolution in vaccine-induced immune thrombotic thrombocytopenia: differential alignment to PF4 ELISA platforms.
Christine S M Lee, Lisa J Clarke, Geoffrey W Kershaw, Ibrahim Tohidi-Esfahani, Timothy A Brighton

Res Pract Thromb Haemost· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Risk of Major Bleeding after Discontinuing Anticoagulation for Unprovoked Venous Thromboembolism: A Systematic Review and Meta-analysis.
Faizan Khan, Alvi Rahman, Tobias Tritschler, Marc Carrier, Clive Kearon, Timothy A Brighton

Thromb Haemost· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel flow cytometry procoagulant assay for diagnosis of vaccine-induced immune thrombotic thrombocytopenia.
Christine S M Lee, Hai Po Helena Liang, David E Connor, Agnibesh Dey, Ibrahim Tohidi-Esfahani, Timothy Andrew Brighton

Blood Adv· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma.
Timothy A Brighton, Amit Khot, Simon J Harrison, David Ghez, Brendan M Weiss

Clin Cancer Res· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis.
Faizan Khan, Alvi Rahman, Marc Carrier, Clive Kearon, Jeffrey I Weitz, Timothy A Brighton

BMJ· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of recurrent venous thromboembolism according to baseline risk factor profiles.
Martin H Prins, Anthonie W A Lensing, Paolo Prandoni, Philip S Wells, Peter Verhamme, Timothy A Brighton

Blood Adv· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis.
Faizan Khan, Alvi Rahman, Marc Carrier, Clive Kearon, Sam Schulman, Timothy A Brighton

BMJ Open· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.
Jeffrey I Weitz, Anthonie W A Lensing, Martin H Prins, Rupert Bauersachs, Jan Beyer-Westendorf, Timothy A Brighton

N Engl J Med· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension.
Philip S Wells, Martin H Prins, Bennett Levitan, Jan Beyer-Westendorf, Timothy A Brighton

Chest· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use.
Ida Martinelli, Anthonie W A Lensing, Saskia Middeldorp, Marcel Levi, Jan Beyer-Westendorf, Timothy A Brighton

Blood· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paris-Trousseau thrombocytopenia is phenocopied by the autosomal recessive inheritance of a DNA-binding domain mutation in FLI1.
William S Stevenson, David J Rabbolini, Lucinda Beutler, Qiang Chen, Sara Gabrielli, Timothy A Brighton

Blood· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study.
Jeffrey I Weitz, Rupert Bauersachs, Jan Beyer-Westendorf, Henri Bounameaux, Timothy A Brighton

Thromb Haemost· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration.
John Simes, Cecilia Becattini, Giancarlo Agnelli, John W Eikelboom, Adrienne C Kirby, Timothy A Brighton

Circulation· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin.
Bruce L Davidson, Sara Verheijen, Anthonie W A Lensing, Martin Gebel, Timothy A Brighton

JAMA Intern Med· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies.
Martin H Prins, Anthonie Wa Lensing, Rupert Bauersachs, Bonno van Bellen, Henri Bounameaux, Timothy A Brighton

Thromb J· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aspirin for preventing venous thromboembolism.
Timothy A Brighton, John W Eikelboom, John Simes

N Engl J Med· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose aspirin for preventing recurrent venous thromboembolism.
Timothy A Brighton, John W Eikelboom, Kristy Mann, Rebecca Mister, Alexander Gallus

N Engl J Med· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT: results of a large Australian study.
Marie-Christine Morel-Kopp, Chee Wee Tan, Timothy A Brighton, Simon McRae, Ross Baker

Thromb Haemost· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The direct factor Xa inhibitor rivaroxaban.
Abhishek K Verma, Timothy A Brighton

Med J Aust· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Platelet function testing in uraemic patients.
Shir-Jing Ho, Rosalie Gemmell, Timothy A Brighton

Hematology· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The direct thrombin inhibitor melagatran/ximelagatran.
Timothy A Brighton

Med J Aust· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Platelet activation in the hypertensive disorders of pregnancy.
Françoise H Harlow, Mark A Brown, Timothy A Brighton, Susan L Smith, Annette E Trickett

Am J Obstet Gynecol· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis